Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.

Dirk Schadendorf(Essen University Hospital), Georgina V. Long(The University of Sydney), Mario Mandalà(University of Perugia), Jacob Schachter, Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Axel Hauschild(University Hospital Schleswig-Holstein), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Richard Kefford(Broad Institute), James Larkin(Royal Marsden NHS Foundation Trust), Laurent Mortier, Victoria Atkinson(The University of Queensland), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Stephanie Manson(Novartis (United States)), Andrew Haydon(The Alfred Hospital), Caroline Robert(Université Paris-Sud), John M. Kirkwood(UPMC Hillman Cancer Center), Ran Ji(Jilin University), Paola Aimone(Novartis (Switzerland))

Journal of Clinical Oncology

May 20, 2018

Cited by 10

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2019|3.7k

|The Lancet|2012|3k

Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.